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Aim: Placenta-specific 1 (PLAC1) is among recently-discovered placental antigens which exerts fundamental role in placental 
function and development. Increasing body of literature shows that PLAC1 is frequently activated and expressed in a wide variety 
of human cancers and promote cancer progression. However, no data is available regarding the expression of mouse orthologue, 
plac1, in murine cancer cell lines. Materials and Methods: We investigated the expression of plac1 in a series of murine cell lines 
from different histological origins, mammary carcinoma (4T1), melanoma (B16F10), colorectal carcinoma (CT26), renal carcinoma 
(Renca), glioma (GL26), B-cell lymphoma (A20 and BCL1) and also two fibroblast cell lines (NIH3T3 and L929), using RT-PCR, 
Western blotting and flow cytometry. Results: Our data demonstrated that plac1 transcript and plac1 protein were expressed in all 
examined cell lines, as judged by RT-PCR and Western blot, respectively. The molecular weight of mouse plac1 was experimentally 
observed to be approximately 24 kD. Flow cytometric analysis showed surface expression of plac1 in aforesaid cell lines ranging 
from 2% to 42.5%. Conclusion: Based on the ubiquitous expression of plac1, the investigated cancer cell lines or immortalized cell 
lines can be used to examine the role of plac1 in the process of immortalization.
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Cancer w�ic� is mainly c�aracterized by uncon-
trolled cell proliferation� resistance to apoptotic deat�� 
metastasis to ot�er tissues� and evasion from immune 
defense mec�anisms� is one t�e most markedly 
causes of mortality in t�e world [�].
Up to t�e present� scientists �ave been employ-
ing several strategies including surgery� radiot�erapy 
and c�emot�erapy to overcome cancer. However� all 
aforesaid strategies are associated wit� undesirable 
damages to normal cells albeit wit� different degrees. 
During t�e last two decades� t�e efficacy and speci-
ficity of t�e immune system �as motivated scientists 
to employ immunot�erapy as a new approac� in order 
to c�allenge wit� malignant cells. In t�is regard� dis-
covering tumor-specific antigens �TSAs� is a milestone 
step in tumor-targeting strategies wit� t�e minimum 
side effects on normal cells. T�ere are� at least� t�ree 
types of tumor antigens including tumor-associated 
antigens �TAAs� [�]� TSAs [�� �]� and cancer/testis an-
tigens �CTAs� [�� 5]. Among t�ese antigens� CTAs are 
expressed on several types of cancer cells albeit t�ey 
are expressed in normal gametes and trop�oblasts. 
In t�is regard� during t�e last decades� CTAs �ave 
been employed as appropriate candidates in cancer 
researc� and biology [5� 6].
PLAC� w�ic� is a member of CTAs and maps 
to c�romosome Xq�6� was first introduced by Coc-
c�ia et al. in ���� [�]. T�e PLAC1 gene is located 
65 kb telomeric to �ypoxant�ine-guanine p�os-
p�oribosyl transferase �HPRT� gene at Xq�6. T�e 
mouse ort�ologue Plac1 maps to t�e equivalent 
region of t�e mouse X c�romosome [�]. Bot� �uman 
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Abbreviations used: anti-rhPLAC1 Ab — anti-rhPLAC1 antibody; 
CTAs — cancer/testis antigens; ELISA — enzyme-linked immu-
nosorbent assay; FBS — fetal bovine serum; HPRT — hypoxan-
thine-guanine phosphoribosyl transferase; HRP — horse radish 
peroxidase; KLH — keyhole limpet hemocyanin; MW — molecular 
weight; OD — optical density; PBS — phosphate-buffered saline; 
PBS-T — PBS + 0.1% Tween 20; PI — pre-immune rabbit immuno-
globulin G; PLAC1 — placenta-specific 1; rhPLAC1 — recombinant 
human PLAC1; RT-PCR — reverse transcription polymerase chain 
reaction; SDS-PAGE — sodium dodecyl sulfate polyacrylamide 
gel electrophoresis; TAAs — tumor-associated antigens; TSAs — 
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PLAC1 and mouse plac1 genes contain 6 exons; 
t�e last exon codes for t�e protein. T�e �uman and 
mouse PLAC1/plac1 genes �ave two promoters [8]. 
PLAC1 promoters are differentially employed in tumor 
cells and placenta [8���]. PLAC1/plac1 transcripts 
started from promoter one �P�� always include 
exons 5 and 6 and may include exons � or � or � but 
always skip exon �; w�ereas transcripts originated 
from promoter two �P�� exclusively include exons �� 
5 and 6 [8]. PLAC1/plac1 genes �ave �5% identity 
at t�e DNA level; �owever� PLAC�/plac� proteins s�ow 
6�% identity at t�e amino acid level [�].
In spite of PLAC� expression in placenta� t�ere 
is evidence indicating PLAC� is �ig�ly activated 
in many types of �uman cancers including breast [���
��]� lung [�����]� liver [��� ��� �5]� colon [������ 
�6��8]� stomac� [��� ��� ��]� ovary [��� ��� ��]� ute-
rus [�� ��]� and cervix [��� ��] and also �uman cancer 
cell lines [��� ��� ��� �5� ��]. We also recently s�owed 
using tissue microarray t�at PLAC� was expressed 
in prostate carcinoma [�5] and could be viewed 
as a suitable candidate target for immunot�erapy 
of �uman prostate cancer [�6].
Up to now� no study is available regarding 
plac� expression in murine cell lines. In t�e present 
study� we assessed t�e plac� expression in cancer 
and immortalized murine cell lines at gene and 
protein levels by reverse transcription polymerase 
c�ain reaction �RT-PCR�� Western blot �WB�� and 
flow cytometry.
MATERIALS AND METHODS
Cell lines and culture conditions. �T�� B�6-F��� 
CT�6� Renca� A��� BCL�� GL�6� L���� NIH�T� murine 
cell lines �all from National Cell Bank of Iran� were 
cultured in RP�I �6�� �Gibco� Invitrogen� CA� USA� 
supplemented wit� ��% fetal bovine serum �FBS� 
�Gibco�� ��� U/ml penicillin� and ��� μg/ml strepto-
mycin in a �umidified incubator at �� ˚C wit� 5% CO�.
Production of polyclonal antibody. Polyclonal 
antibody production� purification� and c�aracterization 
were done as described elsew�ere [��� �8]. Briefly� 
two different types of polyclonal antibodies were 
produced. PLAC� peptide �amino acid residues ����
��8 s�ared in �uman and mice� was first synt�etized 
and conjugated to key�ole limpet �emocyanin �KLH�. 
New Zealand w�ite rabbits were immunized wit� KLH-
conjugated PLAC� peptide. Freund’s complete and 
incomplete adjuvants were used for first and sub-
sequent immunizations� respectively. T�e produced 
antibody was designated as anti-P���. In addition� 
a recombinant �uman PLAC� �r�PLAC�� �amino 
acid residues ��-���� was produced as described 
elsew�ere [��] and injected into New Zealand w�ite 
rabbits. Anti-r�PLAC� antibody �anti-r�PLAC� Ab� 
were t�en purified from sera of immunized rabbits 
using r�PLAC� coupled to a CNBr-activated Sep�a-
rose �B column. T�e purity and reactivity of purified 
antibodies �anti-P��� and anti-r�PLAC� Ab� were 
assessed by sodium dodecyl sulfate polyacrylamide 
gel electrop�oresis �SDS-PAGE� and enzyme-linked 
immunosorbent assay �ELISA�.
Confirmation of PLAC1 specificity of anti-
P117. In order to confirm PLAC� specificity of anti-
P���� several ELISA systems were designed. In one 
experiment� P��� peptide and r�PLAC� protein were 
separately coated overnig�t in ELISA plates. After 
was�ing wit� p�osp�ate-buffered saline �PBS�/�.�% 
Tween �� for t�ree times and blocking wit� 5% bovine 
serum albumin� wells were incubated wit� titrating con-
centrations of eit�er anti-P��� or anti-r�PLAC� Ab for 
� � at �� °C. After was�ing as above� �:���� dilution 
of �orse radis� peroxidase �HRP�-labeled anti-rabbit 
Ig �BioRad� USA� was added to t�e wells and incu-
bation was continued for furt�er � �. In t�e second 
run of experiments� anti-P��� was coated followed 
by sequential addition r�PLAC� ��.�5��� μg/ml for 
� ��� biotin- labeled anti-r�PLAC� Ab ��ouse made� 
�5 μg/ml for � �� and �:������ dilution of HRP-
streptavidin �Invitrogen�. In t�e next experiment� 
r�PLAC� was coated in ELISA wells followed by t�e 
addition of titrating doses of eit�er anti-P��� or P���-
saturated anti-P��� ����-fold molar ratio� for � � and 
HRP-labeled anti-rabbit Ig �BioRad� as above. In all 
ELISA systems� signals were developed by addition 
of tetramet�ylbenzidine and t�e reaction was stopped 
by ��% �v/v� H�SO�. Optical densities were read 
at �5� nm by a p�otometer �BioTek’s Synergy™ ��.
RT-PCR assessment of plac1 expression. 
Cells for RNA purification were �arvested at ���8�% 
confluence. RNA was extracted from cells and mouse 
placenta using ambion PureLink RNA �ini Kit �T�ermo 
Scientific� Walt�am� �assac�usetts� USA� according 
to manufacturer’s recommendations. RNA integrity 
was confirmed by agarose gel electrop�oresis and 
t�e concentration was determined by measuring t�e 
optical density �OD� at �6� nm in a NanoDrop spec-
trop�otometer �T�ermo Scientific�. DNA contamina-
tion was removed using a commercial kit �Sigma� 
�issouri� USA� Product Number: A�PD�� by ap-
plying � μl DNase I to � μg extracted RNA� � μl ��× 
reaction buffer� and adequate water in a total volume 
of �� μl during �� min at RT t�en followed by DNase 
inactivation for �� min at �� °C. First strand cDNA was 
synt�esized using ~� μg ��� μl� of DNA-decontaminat-
ed RNA� � μl 5× reaction buffer �Fermentas� T�ermo 
Scientific�� � μl dNTPs �Roc�e� Basel� Switzerland�� 
� μl N6 random �examers �Fermentas�� � μl reverse 
transcriptase �Fermentas�� and � μl water in a total 
volume of �� μl as follows: �� min at �5 °C� 6� min 
at �� °C and �� mins at �� °C. T�e synt�esized cDNA 
was stored at ��� °C until furt�er use.
A 5�� bp PCR product was amplified using 
plac1 sense 5´-TCAGCAGTGAGCACAAAGCCA-�´ and 
antisense 5´-CAAGGTGAACACGTGGTAGGAAG-�´ 
primers. A t�ree-temperature touc�down PCR pro-
gram was used for DNA amplification: �� °C for 5 min; 
�� cycles at �8 °C for �� s� 65 °C for �� s �wit� tem-
perature decreasing from 65 °C to 56 °C by �.5 °C per 
cycle�� �� °C for �5 s; followed by additional �6 cycles 
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at �8 °C for �� s� 56 °C for �� s� �� °C for �5 s; and a fi-
nal extension at �� °C for 5 min� using a �astercycler 
Gradient Eppendorf t�ermocycler. PCR reactions were 
performed in a �� μl volume containing � μl cDNA� 
�.�5 μl ��� pmoles/μl� of eac� primer� �.5 μl water� and 
�� μl Taq DNA Polymerase �aster �ix RED �Ampliqon� 
Danmark�.
�ouse β-actin was amplif ied as control. 
A ��8 bp β-actin PCR product was amplified using 
sense 5´-GTCGAGTCGCGTCCACC-�´ and antisense 
5´-CATTCCCACCATCACACCCTG-�´ primers. T�e 
PCR amplification was carried out under t�e follow-
ing condition: initial denaturation at �� °C for 5 min� 
a �5-cycle amplification ��8 °C for �� s� 6� °C for �� s� 
and �� °C for �5 s�� and a final extension for 5 min 
at �� °C. PCR reactions was performed in a �� μl vo-
lume containing � μl cDNA� �.�5 μl ��� pmoles/μl� 
of eac� primer� �.5 μl water� and �� μl Taq DNA Poly-
merase �aster �ix RED.
PCR products �expected product size 5�� bp for 
plac1 and ��8 bp for β-actin� were evaluated by �% aga-
rose gel electrop�oresis. Gene expression analysis 
was repeated at least t�ree times for all cell lines.
Protein lysate preparation. Balb/C mouse 
placenta at gestational day �� was dissected and im-
mersed into liquid nitrogen for �� min. T�en� t�e fro-
zen tissue was �omogenized at ������ rpm for � min 
in a �omogenizer �Sartorius �ikro-Dismembrator�. 
T�e tissue was lysed in tris-triton buffer containing 
�� m� Tris-HCl� pH �.�� ��� m� NaCl� � m� EDTA� 
� m� EGTA� �% Triton X-���� ��% glycerol� �.5% 
sodium deoxyc�olate� �.�% SDS� and �% protease 
in�ibitor cocktail �Sigma P8����. T�e lysate protein 
concentration was measured by a BCA protein as-
say kit �T�ermo Scientific� and stored at �8� °C until 
furt�er use.
Human placenta� immediately after Cesa rean 
section� was used for lysis preparation as well. 
An eig�ty milligram sample from villi portion was dis-
sected and prepared in � ml sample buffer containing 
�5� m� Tris pH 6.8� �.�% SDS� ��� m� DTT� ��% 
glycerol� and �.�% bromop�enol blue. T�e tissue was 
sonicated and boiled for �5 min and t�en centrifuged 
at ������ g for �� min at � °C. T�e supernatant was 
stored at �8� °C until furt�er use.
Cells were �arvested at ���8�% confluence wit� 
saline sodium citrate buffer pH 8.� ��5 m� sodium 
citrate and ��� m� potassium c�loride� and was�ed 
t�ree times wit� cold PBS. 5•��6 cells were lysed 
in 5�� μl tris-triton buffer wit� t�e same composition 
as stated above. After �� min incubation on ice� sam-
ples were cleared by centrifugation and supernatant 
was collected and stored at �8� °C.
WB analysis of plac1 expression. r�PLAC� ��� ng 
and �� ng�� a panel of cell lines ��� μl eac��� mouse 
placenta ��� μg�� and �uman placenta ��� μl� were run 
on a �5% SDS-PAGE gel at ��� V for � � and t�en trans-
ferred to PVDF membrane at ��� mA for one �. T�e 
presence of protein bands was confirmed by Ponceau 
S staining. T�e membrane was blocked wit� PBS + 
�.�% Tween �� �PBS-T� containing 5% non-fat milk 
solution overnig�t wit�out s�aking at � °C. All immuno-
probings were performed in PBS-T supplemented wit� 
�% non-fat milk. T�e membrane was incubated wit� 
affinity purified anti-r�PLAC� Ab and pre-immune rabbit 
immunoglobulin G �PI� as a negative primary antibody 
control bot� at � μg/ml for �.5 � wit� s�aking at RT. After 
extensive was�ing� t�e membrane was incubated wit� 
goat anti-rabbit IgG-HRP ��:5���� �Bio-Rad� Hercules� 
California� USA� for one � wit� s�aking at RT followed 
by extensive was�ing and developing wit� Immobilon 
Western C�emiluminescent HRP Substrate detection 
system ��erckmillipore�. Anti-β-actin �clone: D6A8� 
rabbit monoclonal antibody �Cell Signaling Tec�nology� 
Danvers� �assac�usetts� USA� was used for visua-
lization of β-actin after re-probing of t�e membrane. 
Expression level of plac� in all cell lines was tested 
at least t�ree times. Expression of plac� in eac� cell 
line was normalized against β-actin and expressed 
as expression ratio.
Flow cytometric assessment of plac1 locali-
zation. Cells were �arvested at ���8�% confluence 
wit� saline sodium citrate buffer and was�ed t�ree 
times with cold PBS. 5•105 cells were incubated wit� 
5% s�eep serum for �� min on ice. All immunostain-
ings were performed in PBS supplemented wit� �% 
FBS on ice. Cells were subsequently incubated wit� 
eit�er PLAC� peptide �amino acid ���-��8�-immu-
nized rabbit serum ��:���� or a pre-immune rabbit 
serum wit� t�e same dilution for �5 min. After t�ree 
times was�ing� cells were t�en incubated wit� s�eep 
F�ab’�� anti-rabbit polyclonal antibody-FITC ��:���; 
Sina Biotec�� Te�ran� Iran� for �� min in t�e dark. 
Cells were t�en was�ed t�ree times followed by flow 
cytometry analysis using a flow-cytometer �Partec� 
�unster� Germany�.
Statistical analysis. Descriptive statistics were 
carried out.
RESULTS
Production of polyclonal antibodies. In order 
to investigate plac� protein expression in a panel 
of murine cell lines by Western blotting and flow 
cytometry� polyclonal antibodies directed against 
r�PLAC� or P��� peptide were produced. Due to t�e 
fact t�at t�e �uman and mouse PLAC�/plac� pro-
teins �ave 6�% identity [�]� we expected t�at anti-
r�PLAC� antibody could recognize mouse plac�� too. 
Based on t�is rationale� r�PLAC� wit� a molecular 
weig�t ��W� of �� kD was used for immunization 
of rabbits. Also� proper conjugation of t�e P��� peptide 
wit� carrier protein was investigated and confirmed 
by SDS-PAGE �data not s�own�. Titer of purified 
anti-PLAC� antibodies was t�en measured by indirect 
ELISA s�owing proper immunization and �ig� titers 
of anti-PLAC� antibodies in rabbits immunized wit� 
eit�er KLH-conjugated peptide or r�PLAC� �Fig. �� a�. 
To confirm PLAC�-specificity of anti-P���� a sand-
wic� ELISA was designed in w�ic� r�PLAC� was 
first captured by anti-P��� and detected by anti-
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r�PLAC� Ab. T�e results s�owed t�at t�e values 
of optical densities increased wit� increasing concen-
tration of r�PLAC� denoting reactivity of anti-P��� wit� 
r�PLAC� �Fig. �� b�. To furt�er confirm PLAC�-speci-
ficity of anti-P���� an in�ibition ELISA was performed. 
T�e results clearly s�owed t�at P��� peptide was able 
to considerably in�ibit t�e reactivity of anti-P��� wit� 
r�PLAC� furt�er confirming PLAC� specificity of t�e 
polyclonal antibodies directed against amino acids 
���-��� �Fig. �� c�.
Plac1 gene expression in murine cell lines. 
Here we repot for t�e first time t�e plac1 expres-
sion profile in a panel of nine murine cell lines using 
RT-PCR. T�ese cell lines were from different origins 
including mammary carcinoma ��T��� melanoma 
�B�6F���� colorectal carcinoma �CT�6�� renal carci-
noma �Renca�� fibroblast cell lines �NIH�T� and L����� 
glioma cell line �GL�6�� and B-cell lymp�oma cell lines 
�A�� and BCL��. �ouse plac1 contains 6 exons� t�e 
last one codes for t�e protein and exists in four known 
plac1 transcripts [8]. We designed optimal primers 
covering exons 5 and 6 junction to amplify t�e four 
known plac1 mRNA transcripts �Fig. �� a�. T�ese exon-
exon junction primers exclusively guaranteed t�e am-
plification of plac1 transcripts regardless of probable 
genomic DNA contamination in PCR. T�e specificity 
of primers was validated by sequencing of PCR pro-
ducts of mouse placenta� �T�� B�6-F��� and CT�6 cell 
lines �data not s�own�. Interestingly� we observed t�at 
all examined murine cell lines s�owed plac1 gene 
expression �Fig. �� b�. In t�is experiment� mouse pla-
centa and mouse perip�eral blood mononuclear cells 
�PB�C� were used as positive and negative controls� 
respectively. �ouse β-actin gene was used as a �ouse-
keeping internal control gene.
Analysis of plac1 protein expression by WB. Af-
ter approval of plac1 gene expression by RT-PCR in t�e 
examined cell lines� plac� protein expression was t�en 
surveyed using WB. Our results s�owed t�at despite 
excellent reactivity of anti-P��� wit� native protein� t�is 
antibody was not able to detect PLAC� in WB. In t�is 
context� anti-r�PLAC� Ab was used for t�is experi-
ment. Since t�ere is 6�% similarity between �uman 
PLAC� and mouse plac� at t�e protein level [�]� 
we expected t�at anti-r�PLAC� Ab could recognize 
mouse plac�� too. T�e reactivity of t�is antibody 
to PLAC� in �uman placenta as well as r�PLAC� was 
initially confirmed in WB �Fig. �� a�. In negative control 
lanes in w�ic� anti-r�PLAC� antibody was substituted 
wit� equivalent concentration of rabbit normal immu-
noglobulin� no specific band was observed. For detec-
tion of mouse plac� protein in mouse cell lines� we fur-
t�er assessed t�e reactivity of anti-r�PLAC� Ab against 
plac� in mouse placenta lysate as well �Fig. �� a�. 
Data revealed t�at t�is antibody was able to recog-
nize plac� in mouse placenta. Again control wells 
s�owed no specific reactivity. Bot� PLAC� and 
plac� were detected as a s�arp band of approximately 
�� kD in �uman and mouse placenta lysates� respec-
tively. Alt�oug� t�e �W of mouse plac� is t�eoretically 
predicted to be ��.6 kD� t�e �W of plac� protein was 
experimentally s�own to be approximately �� kD. Af-
ter confirming t�e reactivity of anti-r�PLAC� Ab wit� 
its cognate ligand� t�e expression of plac� protein 
was investigated in all examined murine cell lines. 
Interestingly� in all cell lines a band of approximately 
�� kD corresponding to t�e Plac� protein was detected 
wit� anti-r�PLAC� antibody �Fig. �� b�. Notably� t�e 
Fig. 1. Determining specificity of polyclonal anti-plac� anti-
bodies. Two polyclonal anti-PLAC� antibodies directed against 
r�PLAC� and amino acids ���-��8 �P���� were produced 
in rabbits. Bot� antibodies ex�ibited excellent reactivity against 
immunizing antigens �a�. PLAC�-specificity of anti-P��� was 
confirmed by a sandwic� ELISA in w�ic� r�PLAC� was first cap-
tured by anti-P��� and detected by anti-r�PLAC� antibody �b�. 
PLAC�-specificity of anti-P��� was furt�er confirmed by an in�ibi-
tion ELISA. Saturation of anti-P��� by immunizing peptide �P���� 
considerably in�ibited its reactivity wit� r�PLAC� �c�. T�e data 
in �a� and �b� are presented as mean ± SD
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expression ratio of plac� varied between cell lines 
from �istologically different origins. In brief� A�� and 
�T� s�owed t�e �ig�est expression ratio� w�ile t�e 
expression ratio was comparatively lower in CT�6 and 
BCL� �Fig. �� c�.
Flow cytometric analysis of plac1 expres-
sion in murine cell lines. Previous studies s�owed 
localization of �uman PLAC� on cell surface [��� ��]. 
T�e N-terminal side of t�e protein is cytosolic w�ile 
t�e C-terminal region is extracellular. We t�us �ypo-
t�esized t�at� like �uman PLAC�� mouse plac� mig�t 
also be a membranous protein. Hence� plac� loca-
lization was investigated using flow cytometry. In t�is 
experiment� t�e anti-P��� recognizing t�e extracellular 
C-terminal part of t�e plac� was used for plac� loca-
lization in nine examined murine cell lines. Cell �arvest-
ing was done wit� citrate buffer� not wit� trypsinization� 
to protect t�e plac� protein from enzymatic degrada-
tion. Accordingly� it was observed t�at all murine cell 
lines expressed plac� on t�e cell surface albeit wit� 
different expression levels �Fig. ��.
DISCUSSION
PLAC1/plac1 was first introduced by Cocc�ia 
et al. [�] in ���� as a novel placenta-specific gene wit� 
a potential role in placental development. �ost studies 
on t�is molecule were subsequently focused on its ex-
pression in �uman cancer cells and tissues [��� ��� ��]. 
However� t�e expression of mouse ort�ologue� plac�� 
in murine cancer cell lines is largely unclear. Suc� data 
will be of utmost importance w�en t�e potential role 
of plac� in tumorigenesis of mouse cancer cells in syn-
geneic cancer models is investigated. In t�is study� 
we �ave� for t�e first time� analyzed plac� expression 
in nine murine cell lines at bot� gene and protein lev-
els. All examined cell lines expressed plac1 transcript. 
However� t�e expression level was relatively lower 
in B�6F��� GL�6� and BCL� cell lines compared to t�e 
ot�er cell lines. WB analysis also confirmed plac� ex-
pression in all cell lines studied. Here� t�e cell lines ex-
pressed t�e protein at different levels� so t�at CT�6 and 
BCL� cells ex�ibited lower plac� expression ratio w�en 
compared to t�e ot�er cell lines. To study cell surface 
expression� flow cytometric ana lysis was conducted. 
Previous data by in silico analysis of PLAC� topology 
predicted a membranous protein wit� one transmem-
brane �elix [��]. Furt�er experimental studies con-
firmed membranous PLAC� localization [��� ��� ��]. 
To t�is end� we produced a polyclonal antibody against 
a peptide in extracellular region of t�e molecule span-
ning from amino acid ��� to ��8 w�ic� was previously 
used by ot�er investigators in �uman cell lines [��� ��� 
�6� �����]. T�is sequence is common between mouse 
and �uman PLAC�/plac�. Our results s�owed t�at anti-
body directed against amino acid ��� to ��8 is specific 
to plac� as judged by its ability to capture r�PLAC� and 
also by in�ibition of its reactivity wit� r�PLAC� after 
saturation wit� P���-��8. In plac� surface expression 
analysis�
A�� and L��� s�owed relatively �ig�er surface 
expression of plac� t�an t�e ot�er cell lines. Disagre-
ement of t�e results of two protein readout systems 
Fig. 2. Analysis of plac1 transcript expression in murine cell lines. T�e genomic organization of mouse plac1 gene and its expression 
in murine cell lines are s�own. Introns are s�own by solid lines and exons by boxes. Exon 6 contains t�e protein coding sequence. 
primers were designed at t�e exons 5 and 6 junction �a�. RT-PCR analysis of plac1 expression in murine cell lines. �ouse perip�e-
ral blood mononuclear cells �PB�C� and no cDNA control �NC� were used as negative controls. β-actin was used as an internal 
control �b�. DNA ladder: S����� from T�ermo Scientific
�� Experimental Oncology ��� ����� ���� ��arc��
in case of some cell lines points to differential localiza-
tion of plac�.
T�ere is no consensus on �W of �uman PLAC� wit� 
reports ranging from �� to �� kD [��� �6� ��� ��]. 
In t�e present study using anti-r�PLAC� Ab� we ob-
served t�e �W of about �� kD in �uman placenta. 
T�e inconsistent results on PLAC� �W as reported 
in different studies may be attributed to t�e tec�nical 
issues and also to different pattern of post transcrip-
tional modifications in different cells. PLAC� is pre-
dicted to �ave four putative O-glycosyla tion sites 
and five potential p�osp�orylation sites [��]. In t�is 
context� more precise tec�niques suc� as mass 
spectroscopy s�ould be employed to determine 
t�e exact �W of intact purified PLAC� mo lecule. 
In addition� different localization of PLAC�� as re-
ported by many investigators [�5� �6� �8� ��� ��� 
��]� may point to t�e existence of different isoforms 
wit� different �W gene rated by alternative splicing. 
In line wit� t�is notion� we observed in WB a band 
wit� lower �W in �uman and mouse placenta. 
T�e �W of mouse plac� is t�eoretically predicted 
to be ��.6 kD. According to t�e data provided in Ex-
PASy �NetOGlyc �.� and NetP�os �.� servers�� five 
potential O-glycosylation and at least eig�t serine� 
t�reonine or tyrosine p�osp�orylation sites exist 
in plac� molecule w�ic� may account for �ig�er 
�W of plac� reported �ere.
T�ere is growing body of evidence s�owing in-
volvement of PLAC� in promoting vital parameters 
of tumors including cell proliferation� resistance 
to apoptosis� acceleration of cell cycle� progression 
of epit�elial- mesenc�ymal transition and induction 
of cell migration and invasion [��� �5]. In t�is regard� 
blocking of PLAC� protein or silencing of its transcript 
was reported [��� �5] to reverse cancer promoting 
function of PLAC� and may be considered as a mo-
dality to control cancer. Based on t�is information� 
it can be inferred t�at mouse ort�ologue may �ave 
t�e same function in tumorigenesis of mouse can-
cer cell lines. In t�is regard� our data establis�es 
a platform for future studies aiming at potential role 
Fig. 3. WB analysis of plac� protein expression in murine cell 
lines. For assessment of reactivity of anti-r�PLAC� Ab� WB analy-
sis was performed on r�PLAC� and lysates prepared from �u-
man ��Placenta� and mouse �mPlacenta� placenta. Negative 
control lanes were probed wit� equivalent concentration of PI� 
protein ladder: �66�6 from T�ermo Scientific �a�. WB analysis 
of t�e indicated murine cell lines by anti-r�PLAC� antibody. 
T�e pool lysate from all cell lines was used as negative control. 
β-actin was used as internal loading control �b�. Expression 
of plac� in eac� cell line was normalized wit� corresponding 
β-actin and expressed as expression ratio �c�. T�e data in �c� 
are presented as mean ± SD
Fig. 4. Flow cytometric analysis of surface plac� expression 
in murine cell lines. Representative flow cytometric analysis 
of membranous localization of plac� protein in different murine 
cell lines �a�. �ean �SD� of t�ree independent plac� expression 
analyses for eac� cell line is s�own �b�. T�e data in �b� are pre-
sented as mean ± SD
Experimental Oncology ��� ����� ���� ��arc�� ��
of plac� in cancer development in syngeneic mouse 
cancer models.
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